Contact information
Eileen Parkes
MB BCh, Ba(O) (Hons), MRCP (Onc), PhD
ASSOCIATE PROFESSOR, INNATE TUMOUR IMMUNOLOGY, Group leader
- Consultant Medical Oncologist, Early Phase Trials
RESEARCH SUMMARY
- Understand resistance mechanisms to immune-targeting treatments in cancer;
- Characterise the role of the interaction of chromosomal instability and DNA repair deficiency with immune activation in tumour initiation, progression and response.
- Study tumour microenvironment, fibroblasts and extracellular matrix in chromosomally unstable cancers.
In the Parkes Lab we study intrinsic inflammatory pathways in cancer. These are important immune pathways, present in all cells, that act as emergency response pathways to viral infection. However, in cancer, these pathways can be rewired and hijacked by the tumour to promote growth, invasion and metastasis.
Recent publications
-
CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.
Journal article
Skolariki A. et al, (2025), Mol Oncol
-
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Preprint
Lawson NM. et al, (2025)
-
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Journal article
Harrington K. et al, (2025), Future oncology (London, England), 21, 195 - 200
-
IGFs regulate cancer cell immune evasion in prostate cancer
Preprint
Nandakumar AM. et al, (2024)
-
Redefining PD1 as a guardian of stem-like T cells.
Journal article
Jackson M. and Parkes EE., (2024), Nat Rev Immunol